Skip to main content

Advertisement

SpringerLink
Log in

Treatment patterns, use of resources, and costs of advanced non-small-cell lung cancer patients in Spain: results from a Delphi panel

  • Special Article
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

Introduction

Approximately 80–85% of lung cancer patients are diagnosed with non-small-cell lung cancer (NSCLC), of which 50% of patients present with advanced or metastatic disease. The objective of this study was to describe treatment patterns, use of resources and costs associated with treating advanced or metastatic NSCLC patients in Spain.

Methods

A two-round Delphi consensus panel of clinical experts was carried out to describe local clinical patterns based on treatment algorithms from SEOM and ASCO treatment guidelines. The panel consisted of 19 oncologists and 1 hospital pharmacist, who were asked during the first round to define therapeutic pathways for NSCLC by the patients’ performance status, age and histology; to quantify the use of resources associated with the preparation and administration of anticancer pharmacotherapy; management of adverse events associated with anticancer pharmacotherapy; and best supportive care (BSC). The second round was used to try to reduce the variability of responses in some questions and to further describe differences between intravenous and oral therapy. 2009 unit costs were applied to the use of resources described by the clinical experts. The perspective of the study was from the Spanish National Healthcare System.

Results

Performance status guided therapy decision and led to differences in costs. Patients with a performance status of 0–2 were expected to receive anticancer pharmacotherapy while patients with a performance status of 3–4 received BSC including analgesics and corticosteroids. Anticancer pharmacotherapies containing cisplatin or carboplatin were used preferably in first-line treatment, while the usual second- and third-line treatments were docetaxel, erlotinib or pemetrexed monotherapy. The importance of the cost of anticancer pharmacotherapy as a proportion of total healthcare costs was higher for combination therapies containing bevacizumab or pemetrexed. The anticancer pharmacotherapies associated with adverse events like febrile neutropenia or infection increased the total treatment cost. Administration costs were more relevant in regimens containing cisplatin and were low for orally administered therapies. The total cost per patient with advanced or metastatic NSCLC from starting anticancer therapy until death was estimated to be between zs11,301 and zs32,754 depending on the number of treatment lines received.

Conclusions

In the treatment of advanced or metastatic NSCLC, healthcare costs are impacted by line of treatment, patient performance status, type of administration of therapy and adverse event management.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Instituto Salud Carlos III. National Center of Epidemiology (2010) Available at: http://www.isciii.es/htdocs/centros/epidemiologia/epi_cancer.jsp. Accessed: May 2010

  2. Fernández de Larrea-Baz N, Alvarez-Martín E, Morant-Ginestar C et al (2009) Burden of disease due to cancer in Spain. BMC Public Health 9:42

    Article  PubMed  Google Scholar 

  3. Schrump DS, Giaccone G, Kelsey C et al (2008) Non-small cell lung cancer. In: DeVita V, Lawrence T, Rosenberg S. Cancer. Principles & practice of oncology. Lippincott Williams & Wilkins, Philadelphia, USA, pp 896–946

    Google Scholar 

  4. Sant M, Allemani C, Santaquilani M et al (2009) Survival of cancer patients diagnosed in 1995–1999. Results and commentary. Eur J Cancer 45:931–991

    Article  PubMed  Google Scholar 

  5. Abal J, Ramos MA, de la Infanta RG et al (2006) [Lung cancer diagnosis: hospitalization costs]. Arch Bronconeumol 42:569–574

    Google Scholar 

  6. Hirsh V (2010) Systemic therapies in metastatic non-small-cell lung cancer with emphasis on targeted therapies: the rational approach. Curr Oncol 17:13–23

    PubMed  CAS  Google Scholar 

  7. Spiro SG, Tanner NT, Silvestri GA et al (2010) Lung cancer: progress in diagnosis, staging and therapy. Respirology 15:44–50

    Article  PubMed  Google Scholar 

  8. Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al (2005) Erlotinib in previously treated non-smallcell lung cancer. N Engl J Med 353:123–132

    Article  PubMed  CAS  Google Scholar 

  9. Maemondo M, Inoue A, Kobayashi K et al (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362:2380–2388

    Article  PubMed  CAS  Google Scholar 

  10. Sandler A, Gray R, Perry MC et al (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542–2550

    Article  PubMed  CAS  Google Scholar 

  11. Gridelli C, Aapro M, Ardizzoni A et al (2005) Treatment of advanced non-small-cell lung cancer in the elderly: results of an international expert panel. J Clin Oncol 23:3125–3137

    Article  PubMed  CAS  Google Scholar 

  12. Stinchcombe TE, Socinski MA (2009) Current treatments for advanced stage non-small cell lung cancer. Proc Am Thorac Soc 6:233–241

    Article  PubMed  CAS  Google Scholar 

  13. Kadam UT, Jordan K, Croft PR (2006) A comparison of two consensus methods for classifying morbidities in a single professional group showed the same outcomes. J Clin Epidemiol 59:1169–1173

    Article  PubMed  Google Scholar 

  14. Felip E, Garrido P, Trigo JM et al (2009) SEOM guidelines for the management of non-small-cell lung cancer (NSCLC). Clin Transl Oncol 11:284–289

    Article  PubMed  CAS  Google Scholar 

  15. Scagliotti GV, Parikh P, von Pawel J et al (2008) Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage nonsmall-cell lung cancer. J Clin Oncol 26:3543–3551

    Article  PubMed  CAS  Google Scholar 

  16. Azzoli CG, Baker S Jr, Temin S et al (2009) American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 27:6251–6266

    Article  PubMed  CAS  Google Scholar 

  17. E-Salud. Spanish Health Costs Database (2010) Oblikue Consulting. Available at: http://www.oblikue.com/bddcostes/. Accessed: May 2010

  18. General Spanish Council of Pharmacist. Database of Medicines (2010). Available at: http://www.portalfarma.com. Accessed: May 2010

  19. Kosmidis PA, Kalofonos HP, Christodoulou C et al (2008) Paclitaxel and gemcitabine versus carboplatin and gemcitabine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group. Ann Oncol 19:115–122

    Article  PubMed  CAS  Google Scholar 

  20. Heymach JV, Paz-Ares L, De Braud F et al (2008) Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol 26:5407–5415

    Article  PubMed  CAS  Google Scholar 

  21. Fossella F, Pereira JR, von Pawel J et al (2003) Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-smallcell lung cancer: the TAX 326 study group. J Clin Oncol 21:3016–3024

    Article  PubMed  CAS  Google Scholar 

  22. Chang JW, Tsao TC, Yang CT et al (2008) A randomized study of gemcitabine plus cisplatin and vinorelbine plus cisplatin in patients with advanced non-small-cell lung cancer. Chang Gung Med J 31:559–566

    PubMed  Google Scholar 

  23. Georgoulias V, Papadakis E, Alexopoulos A et al (2001) Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial. Lancet 357:1478–1484

    Article  PubMed  CAS  Google Scholar 

  24. Johnson DH, Fehrenbacher L, Novotny WF et al (2004) Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-smallcell lung cancer. J Clin Oncol 22:2184–2191

    Article  PubMed  CAS  Google Scholar 

  25. Hanna N, Shepherd FA, Fossella FV et al (2004) Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22:1589–1597

    Article  PubMed  CAS  Google Scholar 

  26. Quoix E, Breton JL, Ducoloné A et al (2005) First line chemotherapy with gemcitabine in advanced non-small cell lung cancer elderly patients: a randomized phase II study of 3-week versus 4-week schedule. Lung Cancer 47:405–412

    Article  PubMed  Google Scholar 

  27. Jassem J, Ramlau R, Karnicka-Młodkowska H et al (2001) A multicenter randomized phase II study of oral vs. intravenous vinorelbine in advanced non-small-cell lung cancer patients. Ann Oncol 12:1375–1381

    Article  PubMed  CAS  Google Scholar 

  28. Belani CP, Ramalingam S, Perry MC et al (2008) Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced nonsmall-cell lung cancer. J Clin Oncol 26:468–473

    Article  PubMed  CAS  Google Scholar 

  29. Socinski MA, Weissman C, Hart LL et al (2006) Randomized phase II trial of pemetrexed combined with either cisplatin or carboplatin in untreated extensive-stage small-cell lung cancer. J Clin Oncol 24:4840–4847

    Article  PubMed  CAS  Google Scholar 

  30. Giaccone G, Gallegos Ruiz M, Le Chevalier T et al (2006) Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study. Clin Cancer Res 12:6049–6055

    Article  PubMed  CAS  Google Scholar 

  31. Jackman DM, Yeap BY, Lindeman NI et al (2007) Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J Clin Oncol 25:760–766

    Article  PubMed  CAS  Google Scholar 

  32. Lynch TJ, Fenton D, Hirsh V et al (2009) A randomized phase 2 study of erlotinib alone and in combination with bortezomib in previously treated advanced non-small cell lung cancer. J Thorac Oncol 4:1002–1009

    Article  PubMed  Google Scholar 

  33. Georgoulias V, Androulakis N, Kotsakis A et al (2008) Docetaxel versus docetaxel plus gemcitabine as front-line treatment of patients with advanced non-small cell lung cancer: a randomized, multicenter phase III trial. Lung Cancer 59:57–63

    Article  PubMed  Google Scholar 

  34. Gridelli C, Kaukel E, Gregorc V et al (2007) Single-agent pemetrexed or sequential pemetrexed/gemcitabine as front-line treatment of advanced non-small cell lung cancer in elderly patients or patients ineligible for platinum-based chemotherapy: a multicenter, randomized, phase II trial. J Thorac Oncol 2:221–229

    Article  PubMed  Google Scholar 

  35. Chen YM, Perng RP, Shih JF et al (2008) A phase II randomized study of vinorelbine alone or with cisplatin against chemo-naïve inoperable nonsmall cell lung cancer in the elderly. Lung Cancer 61:214–219

    Article  PubMed  Google Scholar 

  36. Navaratnam S, Kliewer EV, Butler J et al (2010) Population-based patterns and cost of management of metastatic non-small cell lung cancer after completion of chemotherapy until death. Lung Cancer 70:110–115

    Article  PubMed  Google Scholar 

  37. Lyseng-Williamson KA (2010) Erlotinib: a pharmacoeconomic review of its use in advanced non-small cell lung cancer. Pharmacoeconomics 28:75–92

    Article  PubMed  Google Scholar 

  38. Rubio-Terrés C, Tisaire JL, Kobina S et al (2002) Cost-minimisation analysis of three regimens of chemotherapy (docetaxel-cisplatin, paclitaxel-cisplatin, paclitaxel-carboplatin) for advanced nonsmall-cell lung cancer. Lung Cancer 35:81–89

    Article  PubMed  Google Scholar 

  39. Sacristán JA, Kennedy-Martin T, Rosell R et al (2000) Economic evaluation in a randomized phase III clinical trial comparing gemcitabine/cisplatin and etoposide/cisplatin in non-small cell lung cancer. Lung Cancer 28:97–107

    Article  PubMed  Google Scholar 

  40. Schiller J, Tilden D, Aristides M et al (2004) Retrospective cost analysis of gemcitabine in combination with cisplatin in non-small cell lung cancer compared to other combination therapies in Europe. Lung Cancer 43:101–112

    Article  PubMed  Google Scholar 

  41. Ferriols Lisart F, Pitarch Molina J, Magraner Gil J (2006) [Pharmacoeconomic assessment of taxanes as first-line therapy for advanced or metastatic nonmicrocytic lung cancer]. Farm Hosp 30:211–222

    Article  PubMed  CAS  Google Scholar 

  42. Carlson JJ, Veenstra DL, Ramsey SD (2008) Pharmacoeconomic evaluations in the treatment of non-small cell lung cancer. Drugs 68:1105–1113

    Article  PubMed  CAS  Google Scholar 

  43. Molinier L, Combescure C, Chouaïd C et al (2006) Cost of lung cancer: a methodological review. Pharmacoeconomics 24:651–659

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medical Oncology Department, University Hospital Lozano Blesa, Zaragoza, Spain

    Dolores Isla

  2. Boehringer Ingelheim España, S.A., Barcelona, Spain

    Nuria González-Rojas

  3. Oblikue Consulting, S.L., Barcelona, Spain

    Diana Nieves & Max Brosa

  4. Boehringer Ingelheim GmbH, Ingelheim am Rhein, Germany

    Henrik W. Finnern

  5. C/ Josep Irla i Bosch, 5-7, 1.a planta, ES-08034, Barcelona, Spain

    Diana Nieves

Authors
  1. Dolores Isla
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nuria González-Rojas
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Diana Nieves
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Max Brosa
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Henrik W. Finnern
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Diana Nieves.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Isla, D., González-Rojas, N., Nieves, D. et al. Treatment patterns, use of resources, and costs of advanced non-small-cell lung cancer patients in Spain: results from a Delphi panel. Clin Transl Oncol 13, 460–471 (2011). https://doi.org/10.1007/s12094-011-0683-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-011-0683-0

Keywords

Search

Navigation